IMMULOGIC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bhag Karamchandani who wrote ()	1/28/1997 9:55:00 AM
From: aknahow	of 305

Bhag, Listened to conference call, asume some posters did and others did not. Sharing impressions can help. #1. IMUL in push to find partners. Traveling in Feb. They feel results of test will help interest potential partners looking for both longer term products and short term product Allervax (1999). Search could include worldwide partners even though allervax is U.S. product. #2 Test proved validity of approach. #3. Low dose 250 given 8 times vs 750 given 4 times has several implications, it explains why they will have to do a 1997 test to validate the low dose results. It also has cost implications, favorable to co. but they will look at smaller vials (container cost goes up with 8 doses but vax. cost goes down). 8 treatments not a big deal in that normal imunologic treatment can run as long as 5 mos.with 40% drop out rate. With 8 over 2 wks drop out rate was 4%. #4 No adverse effects. ////back to partners they will look at medium sized cos that are in the same field of treatment of alergies or respirtory disease. .... Note this post is based on memory as I did not record nor take notes. Would appreciate post by anyone else who listened. Do not know how call will effect stock but the market knows -g-.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next